ライフサイエンスコーパス: muscle biopsy

1 eated disease (symptoms for >2 months before muscle biopsy).

2 myopathy associated with inclusion bodies on muscle biopsy.

3 um of diseases associated with a necrotizing muscle biopsy.

4 or isolation of Sarcocystis species DNA from muscle biopsy.

5 e frequent absence of rimmed vacuoles in the muscle biopsy.

6 arcocystis nesbitti DNA was recovered from 1 muscle biopsy.

7 d avoid issues associated with open skeletal muscle biopsy.

8 e need for invasive diagnostic tests such as muscle biopsy.

9 versally present in patients who underwent a muscle biopsy.

10 most commonly defined by changes observed in muscle biopsy.

11 ng of the gene may preclude performance of a muscle biopsy.

12 rgy radiographic absorptiometry studies, and muscle biopsy.

13 nderlying pathology on biochemistry tests or muscle biopsy.

14 ularly useful to identify suitable sites for muscle biopsy.

15 synthesis rates in skeletal muscle without a muscle biopsy.

16 kness, and specific pathological features on muscle biopsy.

17 derestimated data acquired via more invasive muscle biopsy.

18 in permeabilized muscle fibres prepared from muscle biopsies.

19 alpha-dystroglycan, which can be detected in muscle biopsies.

20 mic clamp, muscle microdialysis studies, and muscle biopsies.

21 e, and the presence of tubular aggregates in muscle biopsies.

22 des, and protein expression were measured in muscle biopsies.

23 milder SMA mouse model and in human patient muscle biopsies.

24 d concurrently in the blood and the repeated muscle biopsies.

25 y of APP in human muscle cell lines and sIBM muscle biopsies.

26 nalyses on protein and RNA isolated from the muscle biopsies.

27 ation in the sarcolemma, as assessed through muscle biopsies.

28 ing (e.g. Akt/mTORC1) by immunoblotting from muscle biopsies.

29 alanine [3-13C] assessed by LC-tandem MS in muscle biopsies.

30 ntification of amyloid deposits in nerve and muscle biopsies.

31 ified 731 known and 325 novel lncRNAs in the muscles biopsies.

32 Sequential muscle biopsies (0, 2 and 6 h) were analysed using confo

33 Two muscle biopsies (0830 and 1400 h) were performed followi

34 We report that in s-IBM muscle biopsies 26S proteasome subunits were immunodetec

35 Half of the muscle biopsies (6/12) showed myopathic changes; increas

36 tially elevated in the serum of mdx mice and muscle biopsies after disease onset.

37 apacity for fatty acid oxidation in skeletal muscle biopsies, along with enhanced efficiency of oxyge

38 d characterization, albeit rarely used, from muscle biopsy analysis.

39 assessed by MRI, muscle strength testing and muscle biopsy analysis.

40 We performed successive muscle biopsies and assessed systemic insulin sensitivit

41 Muscle biopsies and blood samples were collected to asse

42 Ferrochelatase was also severely depleted in muscle biopsies and cultured myoblasts from patients wit

43 relation between ASK1 expression in skeletal muscle biopsies and in vivo insulin action (P = 0.02, r

44 erinsulinemic-euglycemic clamp with skeletal muscle biopsies and indirect calorimetry before and afte

45 However, DUX4 is difficult to detect in FSHD muscle biopsies and it is debatable how robust changes i

46 eport DUX4-fl mRNA and protein expression in muscle biopsies and myogenic cells from genetically unaf

47 y and Western blot in cell samples from both muscle biopsies and primary cultures.

48 New diagnostic modalities based on muscle biopsy and DNA analysis mean that diagnoses withi

49 n magnetic resonance spectroscopy (MRS), and muscle biopsy and fibroblasts were analyzed.

50 Muscle biopsy and immunohistochemical analysis found def

51 ed during 4 h of rest followed by a skeletal muscle biopsy and intravenous glucose tolerance test.

52 of muscles on imaging, myopathic changes on muscle biopsy and loss of calpain 3 protein on western b

53 Other investigations including muscle biopsy and respiratory chain enzyme activity were

54 ted disease (symptoms for </=2 months before muscle biopsy), and 17 had long duration of untreated di

55 ty, lack of precision of protein analysis in muscle biopsies, and absence of mutational hot spots in

56 6,6d2 glucose, d5 phenylalanine, sequential muscle biopsies, and femoral arterial, venous blood samp

57 ed 1) OGTT, 2) euglycemic insulin clamp with muscle biopsy, and 3) (1)H-magnetic resonance spectrosco

58 f histology, immunohistochemical analysis of muscle biopsy, and candidate gene sequencing.

59 bility scores, nerve conduction studies, and muscle biopsies are reported.

60 Tubular aggregates on muscle biopsy are characteristic but may not be apparent

61 Muscle biopsies at 1 year had sustained AAT expression a

62 All patients had muscle biopsies at baseline and week 48.

63 of type 2 diabetes had euglycemic clamps and muscle biopsies before and after acipimox treatment to s

64 Mitochondria were examined in muscle biopsies before and after intervention.

65 Participants had a muscle biopsy before starting treatment and after 12 wee

66 confirmed by magnetic resonance imaging and muscle biopsy; Borrelia burgdorferi infection was confir

67 increased frequency in muscle fibers of sIBM muscle biopsies, but not in non-myopathic muscle or non-

68 analyzed in the CCL-136 muscle cell line and muscle biopsies by immunofluorescence.

69 NM is defined on muscle biopsy by the presence of cytoplasmic rod-like st

70 gs from conventional investigations, such as muscle biopsy, can be misleading.

71 Analysis of muscle biopsies confirmed the presence of aggregates of

72 confounding noise, a 105 sample U133A human muscle biopsy dataset (11 groups: mutation-defined, exte

73 Deep sequencing of the TCR Vbeta region from muscle biopsies demonstrated a limited number of T cell

74 much larger collection of myogenic cells and muscle biopsies derived from biceps and deltoid muscles

75 k muscle strength and oxidative capacity and muscle biopsy-derived measures of damage, mtDNA mutation

76 t myopathic features that were detectable on muscle biopsies, electromyography, muscle magnetic reson

77 ence of alpha-cardiac actin was shown in all muscle biopsies examined, with more alpha-cardiac actin

78 muscles such as those obtained from patient muscle biopsies exhibit a significant decrease in expres

79 Surprisingly, limb or intercostal muscle biopsies exhibit no reduction in AChR numbers or

80 d later or are nonaffected; and (2) in adult muscle biopsies, FAT1 expression is lower in FSHD muscle

81 Typical muscle biopsy features included fibre size variability,

82 with autosomal dominant distal myopathy and muscle biopsy features of both minicores and nemaline ro

83 0 g protein) states after WM and ED by using muscle biopsies, fluorescence-based assays, immunoblot a

84 cytoplasmic inclusions identified in patient muscle biopsies, followed by nanoflow liquid chromatogra

85 nd electromyographic studies, by intercostal muscle biopsies for in vitro microelectrode analysis of

86 st with stable isotope fatty acids, skeletal muscle biopsy for gene expression, and urinary isoprosta

87 To test this model, we studied 125 human muscle biopsies from 13 diagnostic groups (125 U133A, 12

88 We obtained diaphragm muscle biopsies from 22 critically ill patients who rece

89 fluence gene expression, we analyse skeletal muscle biopsies from 271 well-phenotyped Finnish partici

90 Skeletal muscle biopsies from affected patients showed type I (sl

91 Muscle biopsies from all patients exhibited nemaline bod

92 between capillary-fiber ratio (p < 0.01) in muscle biopsies from amputated limbs and Grad measured p

93 ammonia in both plasma samples and skeletal muscle biopsies from cirrhotic patients compared with he

94 An ultra-structural analysis of muscle biopsies from DMD patients suggested that the chr

95 In muscle biopsies from HD patients, there was decreased PG

96 Skeletal muscle biopsies from human patients confirmed the presen

97 Skeletal muscle biopsies from humans with metabolic syndrome afte

98 We also identified RvD2 in skeletal muscle biopsies from humans with peripheral artery disea

99 ategies in mice, together with assessment of muscle biopsies from humans, demonstrated that type I mu

100 Furthermore, human muscle biopsies from individuals who underwent modest di

101 Muscle biopsies from individuals with DMD also had eleva

102 Muscle biopsies from m. vastus lateralis were collected,

103 xylase, and fatty acid transport proteins in muscle biopsies from nondiabetic lean, obese, and type 2

104 Muscle biopsies from patients with sporadic inclusion bo

105 re conducted an expression analysis of human muscle biopsies from patients with T2D; normoglycemic bu

106 Using hamstring muscle biopsies from pediatric patients with CP (n =33)

107 chondrial myopathy, we investigated skeletal muscle biopsies from seven subjects with genetically def

108 etal muscle and spinal cord of SMA mice, and muscle biopsies from SMA patients and controls, using qu

109 By assessing muscle biopsies from subjects with a range of different

110 Muscle biopsies from the m. vastus lateralis were obtain

111 Muscle biopsies from the patients showed dystrophic hist

112 ater than or equal to 8 underwent a skeletal muscle biopsy from the vastus lateralis at median day 5

113 s shown using meta-analysis of over six FSHD muscle biopsy gene expression studies, and validated by

114 bulbar involvement and tubular aggregates on muscle biopsy help to distinguish DPAGT1 CMS from the ma

115 cephalography (EEG), electromyography (EMG), muscle biopsy, high-resolution molecular karyotype array

116 le myopathies may have prominent necrosis on muscle biopsy, immune-mediated myopathies are emphasized

117 ression and protein content were measured in muscle biopsies in 7 lean, 8 obese, and 14 type 2 diabet

118 o address this question, we performed serial muscle biopsies in healthy, lean subjects before and dur

119 n of cytotoxic T cells in the post-treatment muscle biopsies in the two high-dose cohorts.

120 may enable a more rapid diagnosis and avoid muscle biopsy in patients with progressive external opht

121 max) and microcirculation loss on quadriceps muscle biopsy (in CD31(+) immunofluorescence experiments

122 Muscle biopsy, including evaluation of mitochondrial sta

123 lts suggest that the 14-kD actin fragment in muscle biopsies is increased in catabolic states and cou

124 Muscle biopsy is commonly used as an early diagnostic to

125 The staining was performed on archival muscle biopsy material, with subject assignment to norma

126 doubt, a case has not been made for routine muscle biopsy (MB).

127 Muscle biopsies (n = 28), obtained at the level of BOLD-

128 rasonography, electrodiagnostic studies, and muscle biopsies (n = 3).

129 of a number of histopathological findings on muscle biopsy--namely, rimmed vacuoles, an inflammatory

130 Quadriceps muscle biopsies obtained before and after 10 and 60 min

131 by real-time PCR and immunohistochemistry on muscle biopsies obtained before and after therapy from p

132 ted 7 days of bed rest with vastus lateralis muscle biopsies obtained before and after.

133 n sequencing to examine the transcriptome in muscle biopsies obtained from two histologically distinc

134 SINV infection ex vivo by examining a unique muscle biopsy obtained from a patient with chronic myalg

135 Data from a muscle biopsy obtained from a patient with GFPT1 mutatio

136 found reduced alpha-DG glycosylation in the muscle biopsies of affected individuals and in available

137 espiratory chain complexes, were observed in muscle biopsies of affected subjects.

138 omal pathway of intracellular proteolysis in muscle biopsies of CHF patients and healthy controls in

139 nd protein expression plus ultrastructure in muscle biopsies of lowlanders at sea level and following

140 Muscle biopsies of MNGIE patients have revealed morpholo

141 by others to be differentially expressed in muscle biopsies of muscular dystrophy patients.

142 Muscle biopsies of new onset JDM patients showed increas

143 Muscle biopsies of patients were analyzed for atrophy an

144 In muscle biopsies of patients with anti-SRP(+) and anti-HM

145 paring genome-wide gene expression data from muscle biopsies of patients with FSHD to those of 11 oth

146 We found that muscle biopsies of patients with recessive RYR1 mutation

147 The mRNA from 20 muscle biopsies of sIBM, 20 non-inflammatory or dystroph

148 Muscle biopsies of the vastus lateralis and real-time po

149 = 10; and SCA patients, n = 7) and underwent muscle biopsy of the vastus lateralis.

150 bsorptiometry scan, underwater weighing, and muscle biopsy of the vastus lateralis.

151 DMD based on findings of clinical follow-up, muscle biopsy, or direct mutational testing of the DMD g

152 sue elements were observed in seven of eight muscle biopsies performed in the irradiated field; and m

153 Muscle biopsy reliably showed severely reduced or absent

154 Muscle biopsy remains essential in achieving an accurate

155 a clinical phenotype suggestive of CMD, with muscle biopsy reserved as a second-tier investigation.

156 Skeletal muscle biopsies revealed subsarcolemmal accumulation of

157 l and molecular characterization of skeletal muscle biopsies revealed the presence of cytochrome c ox

158 Muscle biopsy revealed a neurogenic pattern with mitocho

159 Electron microscopy of his muscle biopsy revealed abnormal mitochondria.

160 romuscular junction conducted in an anconeus muscle biopsy revealed decreased miniature endplate pote

161 Muscle biopsy revealed lipid accumulation, mitochondrial

162 Muscle biopsy revealed ragged red fibers; mild cerebral

163 A muscle biopsy revealed scattered myofibers with internal

164 Muscle biopsy samples (n=30) were examined by immunohist

165 BM and 30 disease control and normal control muscle biopsy samples and our cultured human muscle fibe

166 ng revealed a substantial Treg population in muscle biopsy samples containing AAT-expressing myofiber

167 nome-wide DNA methylation profiling, as were muscle biopsy samples from 4 healthy controls.

168 and 2 ELR+ CXC chemokines was quantitated in muscle biopsy samples from 7 patients with juvenile DM a

169 Analyses of muscle biopsy samples from children with new-onset juven

170 We analyzed the expression of PDGF-BB in muscle biopsy samples from controls and patients with DM

171 t regenerating and necrotic muscle fibers in muscle biopsy samples from DMD patients expressed PDGF-B

172 We obtained muscle biopsy samples from patients with diabetes who we

173 tial expression of microRNA-126 (miR-126) in muscle biopsy samples from the 2 patient groups and the

174 e transcription-polymerase chain reaction in muscle biopsy samples from the 3 groups.

175 stochemical analyses were performed on human muscle biopsy samples from the patients.

176 Active myopathy was identified in muscle biopsy samples from the patients.

177 Muscle biopsy samples from vastus lateralis and blood sa

178 To address this question, we analyzed muscle biopsy samples from young, lean, insulin resistan

179 stem with which to evaluate abnormalities on muscle biopsy samples obtained from children diagnosed w

180 l scoring system to measure abnormalities on muscle biopsy samples obtained from children with juveni

181 electron microscopy and insulin signaling in muscle biopsy samples obtained from these individuals be

182 se-induced metabolic perturbation assayed in muscle biopsy samples taken from locomotor muscle.

183 Blood and muscle biopsy samples were collected at rest and after e

184 Blood and muscle biopsy samples were collected before and after th

185 emoral arterial and venous blood samples and muscle biopsy samples were collected throughout the stud

186 Repeated blood and muscle biopsy samples were collected to assess whole-bod

187 Venous blood samples and vastus lateralis muscle biopsy samples were obtained during a primed (2.0

188 Muscle biopsy samples were obtained to determine myofibr

189 Skeletal muscle biopsy samples were taken to assess intramuscular

190 ined via the detection of reducing bodies in muscle biopsy sections stained with menadione-NBT follow

191 ominant Vb families were performed in serial muscle biopsy sections to examine whether clonally expan

192 s currently assessed through methods such as muscle biopsy, serum biomarkers, functional testing, and

193 Muscle biopsies showed cytochrome c oxidase-negative fib

194 Analyses of skeletal muscle biopsies showed lower messenger RNA and protein l

195 Muscle biopsies showed myopathic changes, whereas immuno

196 Muscle biopsies showed myopathic features including fibr

197 Muscle biopsies showed ragged-red and cytochrome c oxida

198 Repeated muscle biopsies showed reduction of CD3 lymphocytes by a

199 Muscle biopsies showed variability in fiber size, centra

200 In subject 1, muscle biopsy showed combined oxidative phosphorylation

201 Muscle biopsy showed dystrophic features and reduced alp

202 In all patients, muscle biopsy showed ragged-red and cytochrome c oxidase

203 In all subjects, MTL adjusted for muscle biopsy site (MTLA) was longer than LTL and the LT

204 A muscle biopsy specimen was myopathic with a lack of myop

205 ein levels were measured in human and rodent muscle biopsy specimens after 1 bout of exercise.

206 he findings, especially those related to the muscle biopsy specimens and electromyography, were consi

207 to 39-kDa protein in all 4 diseased skeletal muscle biopsy specimens and in cardiac tissue.

208 ted sharply with the findings in both normal muscle biopsy specimens and JRA synovial tissue specimen

209 Muscle biopsy specimens and serum samples were available

210 Muscle biopsy specimens demonstrated type I fiber atroph

211 Muscle biopsy specimens from 38 of 225 patients showed p

212 btained muscle fiber fragments from skeletal muscle biopsy specimens from adult donors aged 20 to 80

213 Immunohistological and RT-PCR analysis of muscle biopsy specimens from anti-MDA5 and classic DM we

214 naling molecules were determined in skeletal muscle biopsy specimens from BMI- and age-matched overwe

215 High levels of moesin were also observed in muscle biopsy specimens from DMD, Ullrich CMD, and meros

216 Age-matched controls consisted of muscle biopsy specimens from healthy children aged 1 to

217 Muscle biopsy specimens from patients with XLMTM exhibit

218 ream targets ACC-beta, TBC1D1, and TBC1D4 in muscle biopsy specimens obtained from 13 overweight/obes

219 Skeletal muscle biopsy specimens revealed nonspecific myopathic c

220 Muscle biopsy specimens showed markedly thickened endoth

221 Muscle biopsy specimens were collected at each time poin

222 Muscle biopsy specimens were obtained from the vastus la

223 A euglycemic-hyperinsulinemic clamp, muscle biopsy specimens, and magnetic resonance spectros

224 roximately 18,000 genes in each of 113 human muscle biopsy specimens, and studied biopsy specimens an

225 and Western blot analysis were performed on muscle biopsy specimens.

226 mary myotubes prepared from vastus lateralis muscle biopsy specimens.

227 ed by immunofluorescence microscopy in human muscle biopsy specimens.

228 h dystrophic or myopathic changes present in muscle biopsy specimens.

229 muscle metabolism were measured in skeletal muscle biopsy specimens.

230 ter baseline bilateral vastus lateralis (VL) muscle biopsies, subjects consumed 150 ml D2 O (70 atom%

231 ter baseline bilateral vastus lateralis (VL) muscle biopsies, subjects consumed 150 ml D2O (70 atom p

232 Following a first muscle biopsy, subjects in the 'Nutrition' group ingeste

233 Skeletal muscle biopsies taken 24 h after the HIIT exercise showe

234 and mitochondrial function were measured in muscle biopsies taken before and after approximately 2 w

235 accumulations of Parkin protein in skeletal muscle biopsies taken from patients with inclusion body

236 fusion), and 3) saline control with skeletal muscle biopsies taken just before, 30 min after, and 75

237 rimental measurements show that in PAD human muscle biopsies the VEGF165b isoform is at least as abun

238 ggest that high levels of Mi-2 expression in muscle biopsy tissue from patients with DM reflect the p

239 ygous for the expansion, as well as skeletal muscle biopsy tissue, we demonstrate that pre-mRNAs cont

240 In muscle biopsy tissues from anti-HMGCR-positive patients,

241 en performed 3 min all-out tests and donated muscle biopsies to test the second hypothesis.

242 Human skeletal muscle biopsies transplanted into the anterior tibial co

243 METHODS AND In human PAD versus control muscle biopsies, VEGF165b: (1) is elevated, (2) is bound

244 In human PAD versus control muscle biopsies, VEGF165b: (1) is elevated, (2) is bound

245 Biochemical analysis of existing muscle biopsies was correlated with the severity of the

246 Insulin and protein signaling in muscle biopsies was not affected by TNF-alpha.

247 of l-[ring-(13)C6] phenylalanine with serial muscle biopsies was used to measure MPS under baseline f

248 A muscle biopsy was analyzed by light and electron microsc

249 Identification of vasculitis on muscle biopsy was instrumental in recognizing clinical,

250 In the muscle biopsy we found evidence of muscle regeneration d

251 Skeletal muscle biopsies were analysed for mitochondrial volume d

252 Muscle biopsies were collected during a constant stable

253 Additionally, muscle biopsies were collected to assess muscle lipid (f

254 Muscle biopsies were done before, during, and after exer

255 Available muscle biopsies were investigated by standard histologic

256 Human IBM skeletal muscle biopsies were investigated to determine concordan

257 Muscle biopsies were obtained 3 hours, 2 days, and 27 da

258 Muscle biopsies were obtained 4 and 24 h after the 1st,

259 Skeletal muscle biopsies were obtained at each visit, and insulin

260 tentials after direct muscle stimulation and muscle biopsies were obtained at median days 7 and 5, re

261 RESEARCH DESIGN AND Muscle biopsies were obtained basally from lean, obese,

262 and eight controls, serial vastus lateralis muscle biopsies were obtained before and 7 hours after a

263 Muscle biopsies were obtained before and after a 4-month

264 Vastus lateralis muscle biopsies were obtained before and immediately aft

265 Muscle biopsies were obtained from m. vastus lateralis t

266 For this purpose, skeletal muscle biopsies were obtained from nine lowlanders at se

267 Muscle biopsies were obtained from normal adults and thr

268 Basal muscle biopsies were obtained from seven obese (BMI >40

269 Muscle biopsies were obtained from the vastus lateralis

270 ix young (mean age: 25 years) sedentary men, muscle biopsies were obtained from the vastus lateralis

271 Muscle biopsies were obtained from the vastus lateralis

272 Muscle biopsies were obtained from two cohorts of contro

273 Two hours after cryotherapy, muscle biopsies were obtained to analyze changes in the

274 and after the intervention, vastus lateralis muscle biopsies were obtained.

275 Muscle biopsies were performed after 6 wk of training.

276 glycemic-hyperinsulinemic clamp and skeletal muscle biopsies were performed in 73 individuals encompa

277 Muscle biopsies were performed to assess between-group d

278 ps and in vitro analyses of vastus lateralis muscle biopsies were performed.

279 and genetic data as well as muscle MRIs and muscle biopsies were reviewed.

280 Muscle biopsies were stained for galactose-alpha1,3-gala

281 WDM muscle biopsies were studied by Western blotting and imm

282 after 50 ml week(-1) ), further bilateral VL muscle biopsies were taken at 3 and 6 weeks to quantify

283 Further bilateral VL muscle biopsies were taken at 3 and 6 wk to temporally q

284 Muscle biopsies were taken at rest and every approximate

285 Muscle biopsies were taken before and after each clamp.

286 Muscle biopsies were taken before and after training fro

287 Muscle biopsies were taken from 64 old or young male sub

288 00 ECs of the knee extensors with 1 leg, and muscle biopsies were taken from both legs 3 h post-EC.

289 In six of the subjects, muscle biopsies were taken from both legs before and aft

290 Muscle biopsies were taken from eight Trained, Lean sede

291 Muscle biopsies were taken from the m.

292 Muscle biopsies were taken from the m. vastus lateralis

293 Muscle biopsies were taken from the vastus lateralis bef

294 Muscle biopsies were taken to perform high-resolution re

295 Muscle biopsies were used for the isolation of mitochond

296 Ingested (2)H2O and skeletal muscle biopsies were used to measure the 3-d integrated

297 findings in sporadic inclusion-body myositis muscle biopsies with inclusion-body myositis experimenta

298 ne myopathy have a predominantly necrotizing muscle biopsy with minimal lymphocytic infiltration.

299 etal muscle dysfunction and a non-dystrophic muscle biopsy with the presence of one or more character

300 gnetic resonance imaging-directed diagnostic muscle biopsies yielded samples from 20 children with ju